World’s Largest Free Retina Image Gallery & Reference Library

Retina Rocks, the image bank of the Retina World Congress, is a free, open-source online image library whose mission is to help educate the world’s eye care providers about why the retina rocks!

Image Gallery   Over 51,000 multimodal images
Reference Library   Over 14,000 annotated citations from the major eye journals
Cases Atlas   Over 1,550 case studies organized by disease entity
Instagram   Access our Instagram feed @retina.rocks
Wall of Fame   Look here for the best submitted cases and images
 

 

Case of the Day

Have a comment or question about today's case? Go to your favorite social media platform to join the conversation!

ANGIOID STREAKS WITH MACULAR NEOVASCULARIZATION AND TRAUMATIC SUBRETINAL BLOOD

This 45YO female has a history of osteogenesis imperfecta (OI) and complained of several weeks of central vision loss in her right eye. Two months earlier, she was hospitalized following a fall in which she hit the left side of her face, resulting in a concussion and intracranial hemorrhage. Vision was counting fingers OD and 20/20 OS.

Optos color RGB imaging shows bilateral angioid streaks with a peau d’orange appearance to the posterior poles. There are numerous small deep vs subretinal hemorrhages scattered throughout the right macula. Triton swept-source OCT shows cystic retinal thickening. Multiple atypical subretinal hemorrhages mostly parallel the radiating angioid streaks in her left eye. Fundus fluorescein angiography shows diffuse submacular staining OD, a speckled pattern of hypofluorescence from the angioid streaks OU, and blockage from the subretinal blood OS.

Learning Points:

Doyne first described angioid streaks in 1889 as irregular, orange-yellow, crack-like dehiscences in Bruch’s membrane, associated with atrophic degeneration of the overlying RPE. The term “angioid” derives from its resemblance to blood vessels. Although they have historically been mistakenly associated with numerous conditions, the only truly clinically relavent association is with pseudoxanthoma elasticum (PXE; Nadelmann et al, Eye 2023;37:1596-1601). Patients are at significant risk for vision loss from MNV or pattern dystrophy-like changes (Murro et al, Graefe’s 2020;258:1881-1892).

Even minor trauma with angioid streaks can cause subretinal hemorrhaging and choroidal ruptures (Agrawal et al, JAMA Ophthalmology 2017;135(3):e165466). Unlike typical choroidal ruptures, which are usually curvilinear with the nerve, lesions from brittle Bruch’s membrane in PXE appear as numerous irregular ruptures, usually radiating from the nerve. The subretinal hemorrhages in our patient’s left eye were felt to be avascular, unlike the macular neovascularization (MNV) in her right eye.

OI is a genetic disorder that primarily affects type I collagen, leading to bone fragility and various extraskeletal manifestations, including vascular fragility. Ocular manifestations include blue sclerae, increased risk of retinal detachment, and scleral thinning. There is no published association between OI and angioid streaks, other than a single case report of classic PXE-like findings in a patient with OI (Banerjee et al, BMJ Case Rep 2023;16:3256366.doi:10.1136/bcf-2023-256366). However, genetic testing was not reported, so we cannot determine whether this was a chance association with PXE or isolated to OI. Our patient did not have genetic testing due to cost. We suspect our patient has PXE.

Monthly intravitreal injections were started for the MNV in her right eye. Vision improved to 20/30 with complete resolution of all exudation and blood.

Article of the Day

Predictive factors for injection interval extension after switching to faricimab in neovascular AMD: The FAR WEST multicentre study

Posnic A, Yagoub S, Lebastard C, Vaast M, Poinas A, Pabic EL, Bellamy JP, Delhay C, Faure S, Rouic JL, Henry A, Lebreton O, Masse H, Susini F, Guillaumie T, Fournier I, Mainguy A, Lez ML, Khanna RK, Mortemousque G, George A, Pipelart V, Bernard Y, Grimbert P, Mazhar D, Benzerroug M, Briend B, Clement M, Jammes-Veaux HP, Posnic MP, Bonissent A, Guyot C, Rousseau N, Dam BTV, Bellot L, Ferron R, Meur GL, Mouriaux F, Weber M, Maucourant Y, Ducloyer JB.

Acta Ophthalmol. 2026 Sep;104(6):e662-e670. doi: 10.1111/aos.70134.

Summary

nAMD Switching to Vabysmo after prior anti-VEGF for at least 1 year extended the recurrence-free interval — FAR WEST Retrospective, 845 eyes.

Abstract

Purpose: To assess whether switching to faricimab allowed extending injection intervals after 12 months (M12) in patients with neovascular age-related macular degeneration (nAMD) and to identify predictive factors for interval extension.

Design: FAR WEST was a multicentre, observational, retrospective cohort study.

Participants: Patients with nAMD treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections for at least 1 year before switching to faricimab.

Methods: The reason for switching (clinician’s intent to extend the interval in the absence or presence of a recurrence or refractory status), and the switch strategy (whether an induction phase comprising 2, 3 or 4 injections was performed using the same or a shorter interval, or whether the interval was immediately extended from the second injection without induction) were left to the physician’s discretion.

Main outcome measures: The following data were collected from the medical records at the time of the decision to switch to faricimab (M0) and at the M12 follow-up visit: recurrence-free interval, last injection interval, best-corrected visual acuity (BCVA), central macular thickness (CMT), exudation status and intraocular inflammation events.

Results: A total of 845 eyes of 718 patients were included in 23 centres. The recurrence-free injection interval increased significantly from 5.7 weeks at M0 to 8.6 weeks at M12 (difference: +2.9 weeks, p < 0.001). The proportion of exudative patients decreased from 571 (68%) to 337 (42%) (- 41%, p < 0.001). BCVA decreased from 0.33 (20/40) to 0.35 logMAR (20/40) (p = 0.0038). Among 238 refractory cases at M0, 84 (35%) achieved a dry macula at M12. In multivariable analysis, absence of an induction phase was associated with greater injection interval gain. (p < 0.001). There were no differences according to time since the first injection, type of neovascularization. The number of injections per year decreased from 8.7 at M0 to 6.1 at M12 (-2.6, p < 0.001), and the number of consultations decreased from 6.1 at M0 to 5.2 at M12 (-0.9, p < 0.001). The intraocular inflammation rate was 1.6% (n = 14).

Conclusion: Switching to faricimab allowed significantly extending the recurrence-free injection interval, decreasing the proportion of exudative patients and reducing the therapeutic burden in nAMD patients. Further studies are needed to determine the most appropriate switching modalities and which patients actually require an induction phase.

Download Article

Affiliate Societies

Retina Rocks